OncoMed Pharmaceuticals, a US-based cancer treatment developer backed by drugs maker GlaxoSmithKline, has filed for a $115m flotation on the Nasdaq stock exchange.
Investment banks Jefferies and Leerink Swann are co-lead underwriters of OncoMed’s initial public offering (IPO).
The company reports a $15m net loss for 2011 on around $30m in revenue.
Shareholders include GlaxoSmithKline (11.74%) and venture capital firms US Venture Partners (17.28% pre-IPO stake), Latterell Venture Partners (12.19%), Vertical Group (11.22%), Morgenthaler Ventures (10.98%), Phase4 Ventures (9.3%), Delphi Ventures (6.97%) and Adams Street Partners (5.56%).
Phase4 Ventures, the UK-based life sciences corporate venturing unit of Japanese bank Nomura International, spun out as an independent entity in February last year with fund manager HarbourVest Partners.backing a new vehicle that included five existing deals, including Oncomed Pharmaceuticals.